About Us

Medical Oncology

The Division of Medical Oncology was the first of such unit in Singapore to specialise in the systemic treatments for cancer.

We are committed to the highest levels of clinical service and research excellence, and with many drug trials ongoing so that our patients have access to the newest treatments available.

Strong Team-Based, Evidence-based Practice

We are a large team of specialists seeing up 6,000 new cases a year. All consultants are qualified in general oncology, while having a subspecialty focus to maximise the quality of clinical care in that particular area. We are organised into the following sub-specialist teams:

  • Gastro-Intestinal Team: Oesophageal, gastric, intestinal, colon, rectum, anal and hepatobiliary cancers including liver, gallbladder, bile duct
  • Thoracic, Head & Neck, Uro-genital: Lung, mesothelioma, nasopharyngeal carcinoma, kidney, prostate, bladder, germ cell cancers
  • Women’s Cancers: Breast, Ovarian, Cervical, Endometrium
  • Lymphoma and Sarcoma
  • Cancer Genetics
  • Oncology in the Elderly
  • Experimental Cancer Therapeutics Unit (ECRU)

We are continuously upgrading and expanding our clinical services to keep up with the rapid developments in Oncology worldwide.

Our notable achievements include:

  • Conducting the 1st immunotherapy trial in Singapore, where the patient’s own immune system is “reprogrammed” to fight their cancer.
  • Establishment of the the Gastric Cancer Consortium (in partnership with Duke NUS Graduate Medical School and NUH) and the Lung Cancer Consortium (TTSH, KTPH, SGH, CGH, NCCS). These consortiums are testimony to the major role NCCS has nationally and in the region.
  • Setting up of the Investigational Medicine Unit to better understand how new treatments can benefit patients.

Join in the care of cancer patients

The Division of Medical Oncology welcomes staff at all levels to join in the care of cancer patients and there are organised teaching programme for fellows and medical students. Click here to find out more.